Publications

The following includes a selection of recent publications from our lab. View the complete list here on PubMed.

Diffuse midline gliomas with subclonal H3F3A K27M mutation and mosaic H3.3 K27M mutant protein expression

Lopez GY, Oberheim Bush NA, Phillips JJ, Bouffard JP, Moshel YA, Jaeckle K, Kleinschmidt-DeMasters BK, Rosenblum MK, Perry A, Solomon DA.

Acta Neuropathol. 2017; 134 (6): 961-963. doi: 10.1007/s00401-017-1780-0. Epub 2017 Oct 23.

PubMed Link >

Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma

Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA, Barani I, Phillips JJ, Perry A, Okada H.

J Neurooncol. 2016; 130 (3): 543-552. Epub 2016 Sep 13.

PubMed Link >

An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice

Lal S, Carrera D, Phillips JJ, Weiss WA, Raffel C.

Neuro Oncol. 2018 Nov 12; 20 (12): 1606-1615. doi: 10.1093/neuonc/noy089.

PubMed Link >

Pro-angiogenic cellular and genomic expression patterns within glioblastoma influences dynamic susceptibility weighted perfusion MRI

Barajas RF Jr, Phillips JJ, Vandenberg SR, McDermott MW, Berger MS, Dillon WP, Cha S.

Clin Radiol. 2015; 70 (10): 1087-95. doi: 10.1016/j.crad.2015.03.006. Epub 2015 Jul 29.

PubMed Link >

Protein Analysis of Glioblastoma Primary and Posttreatment Pairs Suggests a Mesenchymal Shift at Recurrence

Wood MD, Reis GF, Reuss DE, Phillips JJ.

J Neuropathol Exp Neurol. 2016; 75 (10): 925-935. Epub 2016 Aug 18.

PubMed Link >

Relationship of In Vivo MR Parameters to Histopathological and Molecular Characteristics of Newly Diagnosed, Nonenhancing Lower-Grade Gliomas

Luks TL, McKnight TR, Jalbert LE, Williams A, Neill E, Lobo KA, Persson AI, Perry A, Phillips JJ, Molinaro AM, Chang SM, Nelson SJ.

Transl Oncol. 2018; 11 (4): 941-949. doi: 10.1016/j.tranon.2018.05.005. Epub 2018 Jun 18.

PubMed Link >

Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor

Autry A, Phillips JJ, Maleschlijski S, Roy R, Molinaro AM, Chang SM, Cha S, Lupo JM, Nelson SJ.

Transl Oncol. 2017; 10 (6): 895-903. doi: 10.1016/j.tranon.2017.08.009. Epub 2017 Sep 22.

PubMed Link >

MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival

Radoul M, Chaumeil MM, Eriksson P, Wang AS, Phillips JJ, Ronen SM.

Mol Cancer Ther. 2016; 15 (5): 1113-22. doi: 10.1158/1535-7163.MCT-15-0769. Epub 2016 Feb 16.

PubMed Link >

Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner

Viswanath P, Radoul M, Izquierdo-Garcia JL, Luchman HA, Gregory Cairncross J, Pieper RO, Phillips JJ, Ronen SM.

Cancer Metab. 2018 Apr 3; 6: 3. doi: 10.1186/s40170-018-0178-3. eCollection 2018.

PubMed Link >

Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1

Mazor T, Chesnelong C, Pankov A, Jalbert LE, Hong C, Hayes J, Smirnov IV, Marshall R, Souza CF, Shen Y, Viswanath P, Noushmehr H, Ronen SM, Jones SJM, Marra MA, Cairncross JG, Perry A, Nelson SJ, Chang SM, Bollen AW, Molinaro AM, Bengtsson H, Olshen AB, Weiss S, Phillips JJ, Luchman HA, Costello JF.

Proc Natl Acad Sci U S A. 2017 Oct 3; 114 (40): 10743-10748. doi: 10.1073/pnas.1708914114. Epub 2017 Sep 15.

PubMed Link >